Literature DB >> 19756368

Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD.

Eleonore Rydén1, Christian Johansson, Kaj Blennow, Mikael Landén.   

Abstract

Bipolar disorder with childhood attention-deficit hyperactivity disorder (ADHD) is a subphenotype characterized by earlier age of onset, more frequent mood episodes, more suicide attempts, and more interpersonal violence than pure bipolar patients. The aim of this study was to test the biological validity of using childhood ADHD to subgroup bipolar disorder. The monoamine metabolites, homovanillinic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were determined in the cerebrospinal fluid (CSF) of 53 euthymic patients with bipolar disorder type 1, with (N = 17) and without (N = 36) a history of childhood ADHD. In addition to structured clinical interviews, childhood ADHD was assessed by a next of kin using the Autism-Tics, ADHD and other comorbidities questionnaire (A-TAC), and by patients themselves using the Wender Utah rating scale (WURS-25). Current ADHD symptoms were assessed by the Brown attention-deficit disorder scale (Brown ADD). Bipolar patients with childhood ADHD had significantly lower CSF concentration (mean +/- SD nmol/l) of HVA (89.0 +/- 32.5 vs. 115.8 +/- 47.1, P = 0.039) and 5-HIAA (88.7 +/- 38.5 vs. 116 +/- 47.9, P = 0.021) than pure bipolar patients. CSF MHPG did not differ between the groups. The WURS-25 score correlated negatively with both HVA (r = -0.27, P = 0.048) and 5-HIAA (r = -0.30, P = 0.027). Likewise, the Brown ADD total score correlated negatively with both HVA (r = -0.34, P = 0.013) and 5-HIAA (r = -0.35, P = 0.011). These findings indicate different monoaminergic function in patients with and without childhood ADHD in bipolar disorder type 1. This lends biological support to the notion that those with childhood ADHD represent a valid subphenotype of bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756368     DOI: 10.1007/s00702-009-0300-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  48 in total

Review 1.  Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions.

Authors:  Amy F T Arnsten; Bao-Ming Li
Journal:  Biol Psychiatry       Date:  2005-06-01       Impact factor: 13.382

2.  Psychiatric telephone interview with parents for screening of childhood autism - tics, attention-deficit hyperactivity disorder and other comorbidities (A-TAC): preliminary reliability and validity.

Authors:  Sara Lina Hansson; Annika Svanström Röjvall; Maria Rastam; Carina Gillberg; Christopher Gillberg; Henrik Anckarsäter
Journal:  Br J Psychiatry       Date:  2005-09       Impact factor: 9.319

3.  Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls.

Authors:  G Engström; C Alling; K Blennow; G Regnéll; L Träskman-Bendz
Journal:  Eur Neuropsychopharmacol       Date:  1999-09       Impact factor: 4.600

4.  Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype.

Authors:  S V Faraone; J Biederman; J G Jetton; M T Tsuang
Journal:  Psychol Med       Date:  1997-03       Impact factor: 7.723

5.  The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder.

Authors:  M F Ward; P H Wender; F W Reimherr
Journal:  Am J Psychiatry       Date:  1993-06       Impact factor: 18.112

6.  Monoamine metabolites in CSF and suicidal behavior.

Authors:  L Träskman; M Asberg; L Bertilsson; L Sjöstrand
Journal:  Arch Gen Psychiatry       Date:  1981-06

Review 7.  The genetics of pediatric-onset bipolar disorder.

Authors:  Stephen V Faraone; Stephen J Glatt; Ming T Tsuang
Journal:  Biol Psychiatry       Date:  2003-06-01       Impact factor: 13.382

8.  Evidence for a probenecid-sensitive transport system of acid monoamine metabolites from the spinal subarachnoid space.

Authors:  F W Van der Poel; H M Van Praag; J Korf
Journal:  Psychopharmacology (Berl)       Date:  1977-03-23       Impact factor: 4.530

Review 9.  Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies.

Authors:  M Asberg
Journal:  Ann N Y Acad Sci       Date:  1997-12-29       Impact factor: 5.691

10.  CSF 5-HIAA and DST non-suppression--orthogonal biologic risk factors for suicide in male mood disorder inpatients.

Authors:  Jussi Jokinen; Anna-Lena Nordström; Peter Nordström
Journal:  Psychiatry Res       Date:  2008-12-04       Impact factor: 3.222

View more
  13 in total

Review 1.  Revisiting the serotonin-aggression relation in humans: a meta-analysis.

Authors:  Aaron A Duke; Laurent Bègue; Rob Bell; Tory Eisenlohr-Moul
Journal:  Psychol Bull       Date:  2013-02-04       Impact factor: 17.737

2.  Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder.

Authors:  Ji-Jun Li; Zai-Wang Li; Shu-Zhen Wang; Fang-Hua Qi; Lin Zhao; Hong Lv; An-Yuan Li
Journal:  Psychopharmacology (Berl)       Date:  2011-03-18       Impact factor: 4.530

3.  Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.

Authors:  Joel Jakobsson; Maria Bjerke; Sara Sahebi; Anniella Isgren; Carl Johan Ekman; Carl Sellgren; Bob Olsson; Henrik Zetterberg; Kaj Blennow; Erik Pålsson; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2015-07       Impact factor: 6.186

4.  The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder.

Authors:  Alexander Viktorin; Eleonore Rydén; Michael E Thase; Zheng Chang; Cecilia Lundholm; Brian M D'Onofrio; Catarina Almqvist; Patrik K E Magnusson; Paul Lichtenstein; Henrik Larsson; Mikael Landén
Journal:  Am J Psychiatry       Date:  2016-10-03       Impact factor: 18.112

5.  Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Joel Jakobsson; Henrik Zetterberg; Kaj Blennow; Carl Johan Ekman; Anette G M Johansson; Mikael Landén
Journal:  Neuropsychopharmacology       Date:  2012-11-06       Impact factor: 7.853

6.  Cognitive functioning in clinically stable patients with bipolar disorder I and II.

Authors:  Timea Sparding; Katja Silander; Erik Pålsson; Josefin Östlind; Carl Sellgren; Carl Johan Ekman; Erik Joas; Stefan Hansen; Mikael Landén
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

7.  Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder: evidence in support of mitochondrial dysfunction hypothesis.

Authors:  N Yoshimi; T Futamura; S E Bergen; Y Iwayama; T Ishima; C Sellgren; C J Ekman; J Jakobsson; E Pålsson; K Kakumoto; Y Ohgi; T Yoshikawa; M Landén; K Hashimoto
Journal:  Mol Psychiatry       Date:  2016-01-19       Impact factor: 15.992

8.  Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls.

Authors:  Erik Pålsson; Clara Figueras; Anette G M Johansson; Carl-Johan Ekman; Björn Hultman; Josefin Östlind; Mikael Landén
Journal:  BMC Psychiatry       Date:  2013-06-07       Impact factor: 3.630

9.  Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder.

Authors:  Noriko Yoshimi; Takashi Futamura; Keiji Kakumoto; Alireza M Salehi; Carl M Sellgren; Jessica Holmén-Larsson; Joel Jakobsson; Erik Pålsson; Mikael Landén; Kenji Hashimoto
Journal:  BBA Clin       Date:  2016-04-03

10.  Peripheral blood gene expression profiles linked to monoamine metabolite levels in cerebrospinal fluid.

Authors:  J J Luykx; L M Olde Loohuis; M Neeleman; E Strengman; S C Bakker; E Lentjes; P Borgdorff; E P A van Dongen; P Bruins; R S Kahn; S Horvath; S de Jong; R A Ophoff
Journal:  Transl Psychiatry       Date:  2016-12-13       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.